DNA Script produces synthetic DNA using enzymatic synthesis for use in drug discovery, industrial biotechnology, food technology, and nanotechnologies. The company is headquartered in Paris, France and was founded in 2014 by Thomas Ybert, Sylvain Gariel, and Xavier Gordon.
European Commission and Bpifrance grant
In April 2018, DNA Script announced that it has been awarded $5.5 million in grant funding from the European Commission and French investment bank Bpifrance.
In September 2017, DNA Script closed their Series A round. It was led by Illumina Ventures and joined by Merck Ventures and existing investors Sofinnova Partners, Kurma Partners, and Idinvest Partners. In total they raised a total of €11M.
DNA Script raises a $13,100,000 series A round from Sofinnova Partners, M Ventures, Illumina Ventures, IDInvest Partners and Kurma Partners.
Co-Founder & COO
Co-Founder & CEO
Co-Founder & CTO